TY - JOUR
T1 - Yardstick for Managing Cough, Part 1
T2 - In adults and adolescent patients older than 14 years of age
AU - Irwin, Richard S.
AU - Oppenheimer, John J.
AU - Dunlap, Whitney
AU - Lieberman, Jay A.
AU - Chang, Anne B.
N1 - Funding Information:
Disclosures: Dr Irwin is the chair of the American College of Chest Physicians (CHEST) Expert Cough Panel and codeveloper of the Punum Cough Severity and Punum Cough Quality of Life patient-reported outcome measures that are mentioned in this article. Dr Oppenheimer is a member of the Adjudication/Data and Safety Monitoring Board (DSMB) of AstraZeneca, Novartis, GSK, Abbvie, and Sanofi; a consultant for AstraZeneca, Amgen, GSK, Aquestive, Aimmune, and Regeneron/Sanofi; the executive editor of the Annals of Allergy Asthma and Immunology; the associate editor of AllergyWatch; a reviewer for UpToDate; a section editor for WebMD; and a board member of the American Board of Allergy and Immunology (ABAI) serving as liaison to American Board of Internal Medicine (ABIM). Dr Lieberman is a research investigator (funds to institution) for Aimmune, DBV, Novartis, and Regeneron; is a member of the Adjudication/Data and Safety Monitoring Board (DSMB) for Siolta and Abbvie; served on advisory boards for ALK, DBV, Novartis, and Aquestive; is the associated editor for Annals of Allergy, Asthma, and Immunology; and an executive board member for the American Board of Allergy and Immunology. Dr Chang reports receiving fees (to her institution) as Internal Displacement Monitoring Centre (IDMC) member of an unlicensed vaccine (GSK), an unlicensed monoclonal antibody (AstraZeneca), and coronavirus disease 2019 (COVID-19) for children (Moderna); an advisory member of study design for unlicensed molecules for chronic cough and bronchiectasis (Merck, Zambon, and Boehringer Ingelheim); received personal fees from being an author of 2 UpToDate chapters; and received multiple grants from the National Health and Medical Research Council (NHMRC), Australia. The remaining author has no conflicts of interest to report.
Publisher Copyright:
© 2022 American College of Allergy, Asthma & Immunology
PY - 2023/3
Y1 - 2023/3
N2 - Nationwide statistics in the United States and Australia reveal that cough of undifferentiated duration is the most common complaint for which patients of all ages seek medical care in the ambulatory setting. Management of chronic cough is one of the most common reasons for new patient visits to pulmonologists. Because symptomatic cough is such a common problem and so much has been learned about how to diagnose and treat cough of all durations but especially chronic cough, this 2-part yardstick has been written to review in a practical way the latest evidence-based guidelines most of which have been developed from recent high quality systematic reviews on how best to manage cough of all durations in adults, adolescents, and children. In this manuscript, part 1 of the 2-part series, we provide evidence-based, and expert opinion recommendations on the management of chronic cough in adult and adolescent patients (>14 years of age).
AB - Nationwide statistics in the United States and Australia reveal that cough of undifferentiated duration is the most common complaint for which patients of all ages seek medical care in the ambulatory setting. Management of chronic cough is one of the most common reasons for new patient visits to pulmonologists. Because symptomatic cough is such a common problem and so much has been learned about how to diagnose and treat cough of all durations but especially chronic cough, this 2-part yardstick has been written to review in a practical way the latest evidence-based guidelines most of which have been developed from recent high quality systematic reviews on how best to manage cough of all durations in adults, adolescents, and children. In this manuscript, part 1 of the 2-part series, we provide evidence-based, and expert opinion recommendations on the management of chronic cough in adult and adolescent patients (>14 years of age).
UR - http://www.scopus.com/inward/record.url?scp=85146464626&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2022.12.008
DO - 10.1016/j.anai.2022.12.008
M3 - Article
C2 - 36526233
AN - SCOPUS:85146464626
SN - 1081-1206
VL - 130
SP - 379
EP - 391
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 3
ER -